COMP <GO>
NVAX vs MRK // PIOTROSKI F-SCORE QUALITY
Novavax Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NVAX 7
— MRK 6
▲ PIOTROSKI F-SCORE QUALITY LEADER: MRK
LAST: $10.08 (-3.72%) • MKT CAP: $1.73B
piotroski-score
5/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVAX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVAX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 93.50% | 74.80% | +18.70 | NVAX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 20.70% | +64.30 | NVAX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.3x | 15.3x | -12.00 | NVAX | /valuation <GO> |
| Free Cash Flow Yield | -14.17% | 3.42% | -17.59 | MRK | /fcf-yield <GO> |
| Operating Margin | 40.30% | 34.30% | +6.00 | NVAX | /operating-margins <GO> |
| Net Profit Margin | 39.20% | 28.10% | +11.10 | NVAX | /net-margins <GO> |
| Revenue Growth (YoY) | 64.70% | 1.30% | +63.40 | NVAX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.19 | -4.99 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 51.7 | -3.40 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 18.4x | -14.90 | NVAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.73B | $361.02B | -$359.29B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVAX REV | MRK REV | NVAX GROSS % | MRK GROSS % | NVAX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.12B | $65.01B | 93.5% | 74.8% | -$244.6M | $12.36B |
| FY 2024 | $682.2M | $64.17B | 70.3% | 76.3% | -$87.3M | $18.10B |
| FY 2023 | $983.7M | $60.12B | — | — | -$714.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVAX // BETA —
MRK // BETA 0.92